Compare AbbVie Inc (ABBV) vs Cardinal Health Inc (CAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Cardinal Health Inc — how do they compare? AbbVie Inc trades at $254.63 (market cap $449.91B), while Cardinal Health Inc trades at $239.76 (market cap $56.14B). The key difference: AbbVie Inc is far larger — about 8× Cardinal Health Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CAH | |
|---|---|---|
Market Cap | $449.91B | $56.14B |
Sector | Health | Health |
52-Week High | $261.07 | $239.71 |
52-Week Low | $184.85 | $146.04 |
Enterprise Value | $513.38B | $61.12B |
Dividend Yield | 2.72% | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.63, down 0.84% on the day, with a bullish technical signal and strong support at $248. The stock shows robust fundamentals with revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed to 5.79%. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional accumulation, reinforcing growth prospects beyond Humira's patent expiry.
Outlook remains positive with a consensus price target of $266.33 (5.4% upside), supported by 68% analyst buy ratings. Key opportunities include immunology drugs Skyrizi and Rinvoq driving growth, but risks involve patent cliffs in the 2030s, high debt levels, and regulatory pressures on drug pricing. The stock offers a resilient dividend with recent increases, appealing for income-focused investors amid sector volatility.
Cardinal Health (CAH) trades at $239.71, up 0.32% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats, including Q1 2026 EPS of $3.17 beating estimates of $2.79. Revenue reached $222.58B in 2025 with net income of $1.56B. Technical indicators are bullish, with the current price above key support levels. Analysts maintain a positive outlook with a consensus price target of $243.33.
CAH presents a compelling investment case driven by earnings growth and defensive healthcare distribution. However, risks include high debt levels, thin profit margins, and competitive pressures. The stock's valuation at a P/E of 36.26 may limit upside if growth moderates. Overall, the bullish analyst consensus and operational strength support a positive medium-term view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
